The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Early screening for geographic atrophy may help slow progression to foveal involvement. Collaborating with optometrists on geographic atrophy care is beneficial for patients. Healio spoke with Yasha S ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
An editorial published in the New England Journal of Medicine 1 referred to the Photovoltaic Retina Implant Microarray (PRIMA ...
An oral investigational agent, gildeuretinol (ALK-001), demonstrated a significant reduction in geographic atrophy (GA) lesion growth and improvements in low luminance visual function in the phase II ...
Avacincaptad pegol (Zimura, IVERIC bio) slows the progression of geographic atrophy, results from a phase 3 clinical trial show, giving hope that there will soon be an approved treatment for one of ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. When we think about artificial intelligence ...
Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy is an advanced form of dry age-related macular degeneration, that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback